

## Practical Gynecology, 2<sup>nd</sup> Edition – Chapter 17 References

- \*1. **Weber A, Ziegler C, Belinson J, et al.** Gynecologic history of women with inflammatory bowel disease. *Obstet Gynecol.* 1995;86:843-7.
- \*2. **Taylor S, Drake SM, Dedicoat M, Wood MJ.** Genital ulcers associated with acute Epstein-Barr virus infection *Sex Trans Infect.* 1998;74:29-7.
- \*3. Van Beurden, M M. Normal findings in vulvar examination and vulvoscopy. *Br J Obstet Gynaecol.* 1997;104:320-4.
4. **Prieto MAR, Gutiérrez JV, Sambucety PS.** Vestibular papillae of the vulva. *International J Dermatol.* 43:143-144.
- \*5. **Moyal-Barracco M, Leibowitch M, Orth G.** Vestibular papillae of the vulva: lack of evidence for human papillomavirus etiology. *Arch Dermatol.* 1990;126:1594-8.
- \*6. **Welch JM, NayagamM, ParryG, et al.** What is vestibular papillomatosis? A study of its prevalence, aetiology and natural history. *Br J Obstet Gynaecol.* 1993;100:939–942.
7. **Daley TD.** Pathology of intraoral sebaceous glands: a review. *J Oral Pathol Med.* 1993;22:241-5.
- \*8. **Margesson LJ.** Contact dermatitis of the vulva. *Dermatologic Therapy.* 2004;17:20-27.
- \*9. **Cooper SM, Wojnarowska F.** Influence of treatment of erosive lichen planus of the vulva on its prognosis. *Arch Dermatol.* 2006;142:289-94. *This prospective cohort study followed 114 women with erosive lichen planus of the vulva. Treatment with ultrapotent topical steroids resulted in symptomatic improvement in 94% of subjects, with 71% becoming symptom-free. Treatment with the combined preparation Trimovate (clobetasone butyrate, oxytetracycline, nystatin) resulted in improvement in 100% of subjects, with 93% symptom free. No systemic treatments were consistently effective.*
10. **Marren P, Wojnarowska F, Venning V, et al.** Vulvar involvement in autoimmune bullous diseases. *J Reprod Med.* 1993;38:101-7.
- \*11. **Marren P, Wojnarowska F.** Erosive vulvovaginitis. In: Black MM, McKay M, Braude P, eds. *Obstetric and Gynaecologic Dermatology.* London: Mosby, 1995:125-34.
- \*12. **Powell JJ, Wojnarowska F, Hollowood K, et al.** What is the incidence of lichen sclerosis? *Br J Dermatol.* 2000;143(suppl 57):30.
- \*13. **Oyama N, Chan I, Neill SM, et al: Development of antigen-specific ELISA for circulating autoantibodies to extracellular matrix protein 1 in lichen sclerosis.** *J Clin Invest* 113:1550-1559, 2004. *Most patients with lichen sclerosis have autoantibodies to extracellular matrix protein 1 (ECM-1). These researchers developed an ELISA assay*

and subsequently found that levels of antibody in the serum correlate with disease severity. This test is not yet clinically available.

\*14. **Carli P, Cattaneo A, DeMagnis A, Biggeri A, Taddei G, Giannotti B.** Squamous cell carcinoma arising in vulval lichen sclerosis: a longitudinal cohort study. *Eur J Cancer Prev.* 1995;4:491-5.

\*15. **Jones RW, Sadler L, Grant S, Whineray J, Exeter M, Rowan D.** J Clinically identifying women with vulvar lichen sclerosis at increased risk of squamous cell carcinoma: a case-control study. *Reprod Med.* 2004; 49:808-11. *In women with lichen sclerosis, neither the presence or duration of symptoms nor the loss of vulvar architecture is a useful indicator of potential cancer risk.*

\*16. **Cooper SM, Gao XH, Powell JJ, Wojnarowska F.** Does treatment of vulvar lichen sclerosis influence its prognosis? *Arch Dermatol.* 2004;140:702-6. *This trial studied treatment using class I topical steroids in 327 patients (253 women and 74 girls) with lichen sclerosis. The steroids were effective in relieving symptoms in most and completely reversing skin changes in 23% of subjects.*

17. **Dalziel K, Wojnarowska F, Millard P.** The treatment of vulvar lichen sclerosis with a very potent topical steroid (clobetasol propionate 0.05%). *Br J Dermatol.* 1991;124:461-4.

\*18. **Bornstein J, Heifetz S, Kellner Y, et al.** Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosis. *Am J Obstet Gynecol.* 1998 Jan;178(1 Pt 1):80-4.

\*19. **Le Poole C, Boissy RE.** Vitiligo. *Semin Cutan Med Surg.* 1997;16:3-14.

\*20. **Creasman WT, Phillips JL, Menck HR.** The National Cancer Data Base report on early stage invasive vulvar carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer.* 1997;80:505-13.

21. **Jebakumar S, Woolley PD, Bhattacharyya MN.** Vulvar intraepithelial neoplasia. *Int J STD AIDS.* 1996;7:10-3.

22. **Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000.** *CA Cancer J Clin* 2000; 50:7-33.

23. **Heim K, Widschwendter A, Szedenik H, Geier A, et al.** Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions. *Am J Obstet Gynecol.* 2005;192:1073-83.

\*24. **Jonsson, M, Karlsson, R, Evander, M, Gustavsson, et al.** Acetowhitening of the cervix and vulva as a predictor of subclinical human papillomavirus infection: sensitivity and specificity in a population-based study. *Obstet Gynecol* 1997; 90:744-747

- \*25. **Le T, Menard C, Hicks-Boucher W, et al.** Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. *Gynecol Oncol* 2007;106:579-84.
- \*26. **Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlof B, et al.** Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. *Cancer*. 1999;86:1273-84.
- \*27. **Kodama S, Kaneko T, Saito M, et al.** A clinicopathologic study of 30 patients with Paget's disease of the vulva. *Gynecol Oncol*. 1995;56:63-70.
- \*28. **Zollo JD, Zeitouni NC.** The Roswell Park Cancer Institute experience with extramammary Paget's disease. *Br J Dermatol*. 2000;142:59-65.
- \*29. **Hill DA, Lense JJ.** Office management of bartholin gland cysts and abscesses. *Am Fam Phys*. 1998;57:1611-6.

**AUTHOR: PLEASE PROVIDE REFERENCE #30.**

- \*31. **Masheb RM, Nash JM, Brondolo, Kerns RD.** Vulvodynia: an introduction and critical review of a chronic pain condition. *Pain*. 2000;86:3-10.
- \*32. **Haefner HK, Collins ME, Davis GD, et al.** The Vulvodynia Guideline. *J Lower Gen Tract Dis*. 2005;9:40-51. *This paper is a review of the literature and summary of up-to-date expert opinion in the treatment of vulvodynia. It summarizes local and oral medications, injections and surgical options, and provides an algorithm for treatment.*